About

Vision and strategy

Relaxera is a pharmaceutical company focused on the development of a treatment of the aging heart (Heart Failure with preserved Ejection Fraction – HFpEF) and on protecting pancreatic cells against the glucotoxic effects caused by impaired glucose tolerance.  Our pharmaceutical candidate is relaxin-2, a member of the family of insulin-like hormones, which is released into the blood stream during partition and known for its pleiotropic effects in the human body. Relaxera has developed methods for its synthesis in large quantities and is examining its effects on the heart muscle fibres and on the islet cells of pancreas.

About Relaxera - bringing back vitality

Vision and Strategy

Relaxera Pharmazeutische Gesellschaft mbH & Co. KG (“Relaxera”) is a company dedicated to the development of pharmaceuticals and treatments with human relaxin-2 for chronic cardiovascular diseases and (pre-)diabetic conditions.

In spite of the manifold beneficial actions of relaxin-2 in cardiovascular (patho)physiology Relaxera will focus its activities on the use of synthetic human relaxin-2 for the treatment of the aging heart, heart failure with preserved ejection fraction, and the delay of the onset of type-2 diabetes in obese and overweight patients suffering from impaired glucose tolerance.

Vision and Strategy

Relaxera Pharmazeutische Gesellschaft mbH & Co. KG (“Relaxera”) is a company dedicated to the development of pharmaceuticals and treatments with human relaxin-2 for chronic cardiovascular diseases and (pre-)diabetic conditions.

In spite of the manifold beneficial actions of relaxin-2 in cardiovascular (patho)physiology Relaxera will focus its activities on the use of synthetic human relaxin-2 for the treatment of the aging heart, heart failure with preserved ejection fraction, and the delay of the onset of type-2 diabetes in obese and overweight patients suffering from impaired glucose tolerance.

Patents

Relaxera has taken all necessary actions to protect its intellectual property and ongoing developments. To date, Relaxera owns 17 patents or patent applications from 3 patent families regarding

  • the chemical synthesis of human relaxin-2,
  • relaxin-2 for treating heart failure with preserved ejection fraction (HFpEF), and

  • relaxin-2 for treating impaired glucose tolerance.

Patents

Relaxera has taken all necessary actions to protect its intellectual property and ongoing developments. To date, Relaxera owns 17 patents or patent applications from 3 patent families regarding

  • the chemical synthesis of human relaxin-2,
  • relaxin-2 for treating heart failure with preserved ejection fraction (HFpEF), and

  • relaxin-2 for treating impaired glucose tolerance.

Patents

Relaxera has taken all necessary actions to protect its intellectual property and ongoing developments. To date, Relaxera owns 17 patents or patent applications from 3 patent families regarding

  • the chemical synthesis of human relaxin-2,
  • relaxin-2 for treating heart failure with preserved ejection fraction (HFpEF), and

  • relaxin-2 for treating impaired glucose tolerance.

Owners and advisers

CEO

Prof. Dr. Thomas Bernd Dschietzig

Prof. Dr. Thomas Bernd Dschietzig

CEO of Relaxera, physician, specialist of Internal Medicine

Thomas Bernd Dschietzig’s research has been focused on experimental and clinical studies on the physiology and pathophysiology of human relaxin-2. His work at Charité Hospital – in the research group of Prof. Dr. Gert Baumann and Prof. Dr. Karl Stangl – led to the discovery of the endogenous expression of relaxin in human circulation and its therapeutically beneficial role in chronic human heart failure. These studies earned him the Virchow Prize of the Charité, in 2000, and the Young Investigator Award of the European Society of Cardiology, in 2001.

Dr. Ulrich M. E. Benedum

Dr. Ulrich M. E. Benedum

CEO of Relaxera, patent attorney, PhD in biochemistry

Ulrich Benedum graduated in biochemistry at the European Molecular Biology Lab in Heidelberg. Thereafter, he became a patent attorney who has acquired long-standing experience and has successfully acted as a partner in an international patent lawyer practice handling a broad array of medicinal, biochemical, and technical cases.

CO-FOUNDER

Dr. Ralf Jochem

laboratory physician

Ralf Jochem is a specialist of Laboratory Medicine. He has long since been engaged in supporting and developing innovative business concepts in medicine and laboratory diagnostics.

Prof. Dr. Wolfgang Woloszczuk

biochemist

Wolfgang Woloszczuk is the founder and former CEO of Central European Biomedica Group and now investing in biotechnology start-ups.

Dr. Franz Paul Armbruster

biochemist

Franz Paul Armbruster is founder and CEO of Immundiagnostik AG, a lab diagnostics company long since dedicated to the relaxin field.

Prof. Dr. med. Wolf-Georg Forssmann

pharmacologist

Wolf-Georg Forssmann is CEO of PHARIS Biotec GmbH and one of the most renowned peptide researchers and entrepreneurs.

SCIENTIFIC ADVISORY BOARD
Clinical Advice

Prof. Dr. Stefan Anker

Advice for Cardiovascular Medicine
Berlin-Brandenburg Center for Regenerative Therapies
Charité – University Medicine Berlin, Germany

Prof. Dr. Veselin Mitrovic

Advice for Cardiovascular Medicine
Kerckhoff Clinic Forschungsgesellschaft mbH
Johann Wolfgang Goethe University Frankfurt/Main, Germany

Prof. Dr. Piotr Ponikowski

Advice for Cardiovascular Medicine
Department of Heart Diseases
Medical University, Military Hospital Wroclaw, Poland

Prof. Dr. Philipp Stiegler

Advice for Transplantation Medicine
Medical University of Graz, Austria, Department of Transplantation Surgery, Head of the Department for Surgical Research

SCIENTIFIC ADVISORY BOARD
Basic Research Advice

Prof. Dr. Ross A. D. Bathgate

Co-Leader Discovery Science Theme
Florey Institute of Neuroscience and Mental Health
University of Melbourne,
Australia

Prof. Dr. Chrishan S. Samuel, BSc (Hons)

Deputy Head of Department (Research) & Head, Fibrosis Laboratory in Department of Pharmacology
Deputy Head, Cardiovascular Disease Program in Biomedicine Discovery Institute

Faculty of Medicine, Nursing & Health Sciences
Monash University, Clayton – Victoria, Australia

Prof. Dr. M. Akhter Hossain

Head, Insulin Peptides Laboratory
Florey Institute of Neuroscience and Mental Health
University of Melbourne,
Australia